Kimmtrak Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

(MENAFN- GlobeNewsWire - Nasdaq) Key market opportunities for Kimmtrak include expansion into additional melanoma indications and targeted immunotherapies, a growing elderly population, increased oncology investment, bispecific immunotherapies, precision oncology, and rising focus on rare cancer treatments.

Dublin, May 07, 2026 (GLOBE NEWSWIRE) -- The "Kimmtrak Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets's offering.

The growth in the historic period can be attributed to limited options for uveal melanoma, advances in immuno-oncology science, orphan drug incentives, increased cancer genomics research, and regulatory support for rare cancers. The forecasted period points to expansion into additional melanoma indications, growth in targeted immunotherapies, improved early diagnosis, increased oncology investment, and global orphan oncology market growth. Major trends include growth in T cell engaging therapies, a rising focus on rare cancer treatments, expansion of bispecific immunotherapies, advancements in precision oncology, and increased orphan drug development.

The rising prevalence of uveal melanoma is expected to significantly contribute to the growth of the Kimmtrak market. Uveal melanoma, an aggressive cancer originating in the eye, is driven by genetic mutations. Kimmtrak activates T-cells to recognize and destroy these melanoma cells, enhancing patient outcomes. The American Cancer Society reported approximately 3,320 new eye and orbit cancer diagnoses annually, with significant mortality figures, highlighting the increasing demand for effective treatments like Kimmtrak.

The aging population is projected to propel the Kimmtrak market, with the elderly facing age-related health challenges. Kimmtrak provides a critical treatment option for the older demographic with uveal melanoma, boosting immune systems to target cancer. The Population Reference Bureau reported a significant increase in the elderly population, which is expected to expand Kimmtrak's market as this demographic grows.

A trend in the Kimmtrak market is the integration of innovative T-cell receptor (TCR) therapies into healthcare systems, obtaining HTA reimbursement approvals to increase accessibility. In December 2024, Immunocore Holdings plc. achieved NICE approval to provide Kimmtrak through England's NHS, enhancing access to advanced cancer treatments.

North America emerged as the largest region in the Kimmtrak market in 2025, with Asia-Pacific anticipated to grow fastest. Regions covered include Asia-Pacific, Western and Eastern Europe, North and South America, Middle East, and Africa, with specific attention to major markets like the USA, UK, and China.

Market dynamics show tariffs affecting costs in biologic manufacturing and logistics, prompting localized partnerships and improved supply chain security. The Kimmtrak market research report offers insights into industry size, regional shares, market segments, trends, and opportunities, enabling stakeholders to navigate the industry's current and future landscapes.

Kimmtrak (tebentafusp) is a bispecific TCR therapy targeting unresectable or metastatic uveal melanoma. By binding to melanoma cell proteins and T-cell receptors, it triggers an immune response that combats cancer. Available in injectable formulations, Kimmtrak is applied across patient demographics and distributed through various channels including wholesalers and pharmacies. The market includes sales of pre-filled syringes and vial-based concentrates, with values representing manufacturer sales without supply chain resales.

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN07052026004107003653ID1111082231